DJIA 17,827.75 0.00 0.00%
NASDAQ 4,787.32 0.00 0.00%
S&P 500 2,072.83 0.00 0.00%
market minute promo


company name or ticker

Belviq Sales Dip: What To Watch For Ahead

Biotech Stock Mailbag: Small-Cap Rebound, Avanir, Ohr, CytoSorbents

What To Watch For As Orexigen's Launch Approaches

Pfizer Setback Could Help Arena

Belviq Sales Rise Almost 5% Week Over Week

Eisai And Arena Pharmaceuticals Announce Publication Of Pooled Phase 3 Clinical Trial Analysis Of BE

Eisai And Arena Pharmaceuticals Announce Publication Of Pooled Phase 3 Clinical Trial Analysis Of BELVIQ (lorcaserin HCl) CIV In Postgraduate Medicine

3 Biotech Stocks Near 52-Week Lows Worth Buying

These may be cheap biotech stocks, but they may not be cheap for long according to the three analysts we asked.

The 1 Biotech Stock I'm Definitely Not Buying

Three of our analysts chime in on which biotech stocks they think are the most risky.

Orexigen On A Tear - In The Wrong Direction

Why Is Sanofi Betting on MannKind Corporation's Afrezza?

Sanofi's global dominance over the lucrative diabetes market is facing a serious challenge with the patent expiration of Lantus, the most commonly prescribed insulin in the world. Can MannKind's inhaled insulin product help Sanofi retain its edge?
See More Articles...